SAFE

Treatment tested

• Teriflunomide

  Dihydroorotate dehydrogenase inhibitor

Other measures (6)

Inclusion criteria: * Age of patients ≥ 18 years * Patients with relapsing form of multiple sclerosis at time of screening visit. * Signed written informed consent. Exclusion criteria: * Patients with hypersensitivity to teriflunomide, leflunomide, or to any excipients in the tablets. * Liver function impairment or persisting elevations of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), greater than two times the upper limit of normal (ULN) during screening visit. * Known history of pre-existing acute or chronic liver disease. * Patients with significantly (as per Investigator's discretion) impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia. * Known history of severe immunodeficiency, acute or severe active infections. * Female patients with a positive pregnancy test at screening or women of child-bearing potential who do not agree to use effective methods of contraception throughout the course of the study. * Male patients unwilling to use reliable contraception during the course of the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary Objective: To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis. Secondary Objective: To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.